Chromogenic Factor VIII Inhibitor Bethesda Titer, Plasma
Use
Detects the presence and titer of specific inhibitors against coagulation factor VIII, which are IgG antibodies. These inhibitors can develop either alloimmune in patients with congenital FVIII deficiency due to therapeutic infusions of factor VIII concentrate, or autoimmune in patients without hemophilia usually manifesting during pregnancy or associated with autoimmune disorders, potentially resulting in life-threatening hemorrhage.
Special Instructions
Not provided.
Limitations
The test is specifically designed to detect inhibitors of coagulation factor VIII and is not suitable for detecting other clotting factor inhibitors or lupus anticoagulants. Spurious results can occur with contamination due to improper specimen collection techniques, such as through an IV line without proper wasting or above a running fluid line.
New York Approved
Methodology
Chromogenic
Biomarkers
Factor VIII Inhibitor
Analyte
LOINC Codes
- 93450-5 - Fact VIII Inhib PPP Chro-aCnc
- 93450-5 - Fact VIII Inhib PPP Chro-aCnc
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
2 mL
Minimum Volume
1 mL
Container
Plastic vials
Collection Instructions
Collect prior to factor replacement therapy. Centrifuge, transfer plasma to plastic vial, centrifuge again, aliquot into 2 vials leaving 0.25 mL and freeze immediately.
Storage Instructions
Freeze at -20 degrees C or preferably -40 degrees C within 4 hours.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus, IV heparin contamination
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |